Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16.07. | Eton Pharma Announces FDA Acceptance Of NDA For ET-400; Stock Up In After-hours | 1 | RTTNews | ||
15.07. | Eton Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
15.07. | Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution) | 62 | GlobeNewswire (Europe) | - Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals... ► Artikel lesen | |
21.06. | Eton Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.06. | Eton Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
09.05. | Eton Pharmaceuticals GAAP EPS of -$0.03, revenue of $8M | 1 | Seeking Alpha | ||
09.05. | Eton Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
09.05. | Eton Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
08.05. | Eton Pharmaceuticals Q1 2024 Earnings Preview | 1 | Seeking Alpha | ||
01.05. | Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference | 1 | GlobeNewswire (USA) | ||
30.04. | Eton Pharmaceuticals Announces NDA Submission For ET-400 | 1 | RTTNews | ||
30.04. | Eton Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.04. | Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution) | 167 | GlobeNewswire (Europe) | - Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually -- Product... ► Artikel lesen | |
29.04. | Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 | 1 | GlobeNewswire (USA) | ||
18.04. | Eton Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
26.03. | Eton Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
22.03. | Eton Pharmaceuticals, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
22.03. | Eton Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
22.03. | Relief Therapeutics grants exclusive U.S. rights to Eton Pharmaceuticals for PKU GOLIKE | 3 | Seeking Alpha | ||
22.03. | Eton Pharma Buys U.S. Rights To PKU GOLIKE From Relief Therapeutics | 4 | RTTNews |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 27,465 | -0,24 % | Bayer-Aktie an DAX-Spitze: Charttechnisch spannend | Mit einem Plus von gut drei Prozent rangiert das Papier von Bayer zu Wochenbeginn an der Spitze im DAX. Neuigkeiten von Unternehmens- oder Analystenseite, die die recht deutlichen Kursaufschläge begründen... ► Artikel lesen | |
PFIZER | 28,375 | +0,11 % | Pfizer Aktie: Prognosen für Q2 2024 | Die Pfizer-Aktie steht vor einer herausfordernden Periode, da Analysten für das zweite Quartal 2024 einen Gewinnrückgang bei steigendem Umsatz erwarten. Prognosen deuten auf einen Quartalsgewinn von... ► Artikel lesen | |
NOVO NORDISK | 116,52 | -0,14 % | Diese Aktie schlägt Novo Nordisk um Längen | Für die Medikamente von Novo Nordisk gegen Fettleibigkeit (Adipositas) und Diabetes werden immer neue Anwendungsgebiete gefunden: Die Bestseller Ozempic und Wegovy verkaufen sich wie warme Semmeln -... ► Artikel lesen | |
GILEAD SCIENCES | 70,88 | -0,08 % | Gilead's Twice-yearly Injection Offers 100% Protection Against HIV In Women: Study | FOSTER CITY (dpa-AFX) - In a recent study conducted by Gilead Sciences, Inc. (GILD) and published in the New England Journal of Medicine, it was revealed that a biannual injection of lenacapavir... ► Artikel lesen | |
ABBVIE | 170,58 | +0,01 % | European Commission Approves AbbVie's Skyrizi To Treat Ulcerative Colitis | WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV) on Friday said the European Commission has approved Skyrizi for the treatment of adults with ulcerative colitis.Ulcerative colitis is a type of inflammatory... ► Artikel lesen | |
ASTRAZENECA | 144,35 | +1,09 % | JPMORGAN stuft ASTRAZENECA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Astrazeneca auf "Overweight" mit einem Kursziel von 13000 Pence belassen. Die am Donnerstag anstehenden Quartalszahlen des Pharmakonzerns dürften... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 458,75 | +0,54 % | Is Vertex Pharmaceuticals' Monopoly in Danger? | ||
EYEPOINT PHARMACEUTICALS | 8,750 | +4,42 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
ASTRIA THERAPEUTICS | 11,300 | +2,73 % | Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress | Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two... ► Artikel lesen | |
OPKO HEALTH | 1,287 | +2,96 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results | MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights... ► Artikel lesen | |
LIGAND PHARMACEUTICALS | 99,00 | 0,00 % | Ligand Aktie: Übernahme von APEIRON Biologics | Strategischer Zuwachs für Ligand Ligand Pharmaceuticals hat eine bindende Vereinbarung zur Übernahme der österreichischen APEIRON Biologics AG für 100 Millionen US-Dollar getroffen. Diese Akquisition... ► Artikel lesen | |
EXSCIENTIA | 4,960 | +0,40 % | Exscientia plc: Exscientia erwirbt volle Rechte an potenziellem CDK7-Inhibitor der Spitzenklasse vor der Veröffentlichung von Phase-1-Dosis-Eskalationsdaten | Maximierung des Potenzials von GTAEXS617 mit Präzisionsdesign durch Erwerb der Rechte von GT Apeiron Veröffentlichung der Dosis-Eskalationsdaten für die Phase-1/2-Studie ELUCIDATE in der zweiten... ► Artikel lesen | |
JAZZ PHARMACEUTICALS | 102,75 | -0,05 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026 | DUBLIN, July 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that it has completed a repricing of the approximately $2.7 billion... ► Artikel lesen | |
ROYALTY PHARMA | 26,560 | +0,15 % | Should You Consider Adding Royalty Pharma plc (RPRX) to Your Portfolio? | ||
CATALYST PHARMACEUTICALS | 16,100 | -0,59 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE in Canada | CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen |